General Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations. In: United States Pharmacopeia and National Formulary (USP 43-NF 38). Revised January 1, 2014. Rockville, MD: The United States Pharmacopeia Convention Inc; 2020.
Commercially available as a 10-mg/mL solution — Use extemporaneously prepared formulation only when commercial product is unavailable or a more concentrated suspension is desired. Extemporaneously prepared suspension may not achieve same bioavailability as commercially available formulation. Monitoring of serum itraconazole concentration may be warranted.
Abdel-RahmanSM, NahataMC.Stability of itraconazole in an extemporaneous suspension. J Ped Pharm Pract. 1998;3:115–118.
Abdel-RahmanSM, NahataMC.Stability of itraconazole in an extemporaneous suspension. J Ped Pharm Pract. 1998;3:115–118.)| false
ChristensenKJ, GubbinsPO, GurleyBJ, et al.Relative bioavailability of itraconazole from an extemporaneously prepared suspension and from the marketed capsules. Am J Health Syst Pharm. 1998;55:261–265.10.1093/ajhp/55.3.261)| false